Actos
Total Payments
$14.7M
Transactions
1,691
Doctors
61
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $855,642 | 101 | 7 |
| 2018 | $6.0M | 1,011 | 34 |
| 2017 | $7.8M | 579 | 22 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.7M | 1,650 | 99.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,975 | 1 | 0.1% |
| Travel and Lodging | $10,862 | 4 | 0.1% |
| Consulting Fee | $1,175 | 1 | 0.0% |
| Food and Beverage | $803.03 | 35 | 0.0% |
Payments by Type
Research
$14.7M
1,650 transactions
General
$26,815
41 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Development Center Americas, Inc. | $7.6M | 5 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $6.7M | 23 |
| MCI Convertors from study 301 | Takeda Development Center Americas, Inc. | $171,876 | 0 |
| MCI Convertors from study 301 | Takeda Pharmaceuticals U.S.A., Inc. | $152,014 | 0 |
| Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease | Takeda Pharmaceuticals U.S.A., Inc. | $12,722 | 0 |
Top Doctors Receiving Payments for Actos
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $14.6M | 1,584 |
| , MD | Endocrinology, Diabetes & Metabolism | New Orleans, LA | $25,050 | 5 |
| , MD | Geriatric Psychiatry | Seattle, WA | $19,880 | 2 |
| , MD | Psychiatry | Los Angeles, CA | $15,810 | 4 |
| , M.D | Neurology | Chicago, IL | $7,525 | 1 |
| , MD | Neurology | Indianapolis, IN | $7,380 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $6,750 | 2 |
| , MD | Family Medicine | Kissimmee, FL | $4,828 | 3 |
| , MD | Adult Reconstructive Orthopaedic Surgery | Temple Terrace, FL | $3,157 | 5 |
| , MD | Psychiatry | Middleton, WI | $3,050 | 4 |
| , MD | Family Medicine | Daytona Beach, FL | $2,525 | 2 |
| , M.D | Neurology | Decatur, GA | $1,677 | 2 |
| , MD | Neurology | Salt Lake City, UT | $1,620 | 8 |
| , MD | Clinical Neurophysiology | Phoenix, AZ | $1,419 | 3 |
| , M.D | Pain Medicine | Philadelphia, PA | $1,394 | 1 |
| , MD | Psychiatry | Canton, OH | $1,175 | 1 |
| , MD | Psychiatry | Charleston, SC | $1,174 | 4 |
| , MD | Medical Oncology | Baltimore, MD | $1,136 | 2 |
| , MD | Family Medicine | St Petersburg, FL | $1,111 | 2 |
| , M.D | Neurology | Cordova, TN | $1,063 | 4 |
| , M.D | Neurology | Elk Grove Village, IL | $707.00 | 2 |
| , MD | Internal Medicine | Concord, NC | $686.80 | 3 |
| , M.D | Psychiatry | Denver, CO | $606.00 | 2 |
| , M.D | Hematology & Oncology | New York, NY | $585.80 | 1 |
| , M.D | Internal Medicine | Portland, OR | $404.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $14.7M
- Total Doctors 61
- Transactions 1,691
About Actos
Actos is a drug associated with $14.7M in payments to 61 healthcare providers, recorded across 1,691 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Development Center Americas, Inc..
Payment data is available from 2017 to 2019. In 2019, $855,642 was paid across 101 transactions to 7 doctors.
The most common payment nature for Actos is "Unspecified" ($14.7M, 99.8% of total).
Actos is associated with 5 research studies, including "Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD" ($7.6M).